1594092-37-1
1594092-37-1
Chemical Structure
AZ191
- CAS No.: 1594092-37-1
- Formula:C24H27N7O
- Molecular Weight:429.52
IUPAC Name: N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-amine
InChIKey: ZYVXTMKTGDARKR-UHFFFAOYSA-N
SMILES: CN1C2=CN=CC=C2C(C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4OC)=NC=C3)=C1
Biological Activity: AZ191 is a potent inhibitor that selectively inhibits DYRK1B with IC50 of 17 nM[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZ191 | 99.87% | AZ191 is a potent inhibitor that selectively inhibits DYRK1B with IC50 of 17 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rezivertinib analogue 1 (Standard) | ≥98% | Rezivertinib analogue 1 (Standard) is the analytical standard of Rezivertinib analogue 1. This product is intended for research and analytical applications. Rezivertinib analogue 1 is a process impurity of osimertinib mesylate. Rezivertinib analogue 1 can be used in the study of non-small cell lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EGFR-IN-77 | EGFR-IN-77 (Compound 4a) is a selective EGFRT790M/L858R inhibitor, with an IC50 of 0.101 μM against EGFRT790M/L858R, 0.477 μM against EGFRL858R, and 1.771 μM against wild-type EGFR. EGFR-IN-77 exerts selective antiproliferative effects on EGFRT790M/L858R non-small cell lung cancer. EGFR-IN-77 can be used for the research of EGFRL858R/T790M double-mutant non-small cell lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AZD-3463 | 99.31% | AZD-3463 (ALK/IGF1R inhibitor) is an orally active ALK/IGF1R inhibitor, with a Ki of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Osimertinib (GMP Like) | Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HG-14-10-04 | 98.53% | HG-14-10-04 is a potent ALK and mutant EGFR inhibitor with IC50s of 20 nM, 15.6 nM, 22.6 nM and 124.5 nM for ALK, EGFRLR/TM, EGFR19del/TM/CS and EGFRLR/TM/CS, respectively. HG-14-10-04 can be used to research anticancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EGFR T790M/L858R-IN-5 | EGFR T790M/L858R-IN-5 (example 52) is a potent inhibitor of EGFR T790M/L858R with the inhibition percentage of 92.9% in the concerntration of 0.05 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EGFR T790M/L858R-IN-6 | EGFR T790M/L858R-IN-6 (compound 53), a pyrimidine compound, is a potent EGFR T790M/L858R inhibitor. EGFR T790M/L858R-IN-6 shows 90.88% enzyme activity inhibition with 0.05 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mutated EGFR-IN-1 | 99.90% | Mutated EGFR-IN-1 (Osimertinib analog) (Intermediate 168) is a structural analog of Osimertinib (HY-15772) and can be used as a pharmaceutical intermediate for EGFR inhibitors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AZ7550 | 97.09% | AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AZ7550 hydrochloride | AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
